ArticleArthroplasty today2026
Antiresorptive Therapy and Revision Risk After Primary Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Article in Arthroplasty today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This systematic review evaluates whether the use of bisphosphonates or denosumab influences the rate of revision and aseptic loosening after primary total knee arthroplasty (TKA). Additionally, the effects of antiresorptive therapy on periprosthetic fracture risk, bone mineral density (BMD) loss, and migration after TKA were evaluated, along with the potential adverse effects associated with these therapies. Methods: A systematic review and meta-analysis were conducted using PubMed, Cochrane Library databases, and gray literature between January 2009 and July 2025 to identify studies evaluating bisphosphonate or denosumab use after primary TKA. Results: After screening 253 results, 12 studies encompassing 426,920 patients met the inclusion criteria, with 4 studies eligible for meta-analysis. There were 7 randomized controlled trials) and 5 prospective/retrospective cohort studies; meta-analytic estimates were derived exclusively from registry-based cohorts. Bisphosphonate use was associated with a significantly lower rate of all-cause revision (1.37% vs 2.71%; Conclusions: Bisphosphonate therapy after TKA is associated with a lower risk of all-cause revision; however, the certainty of evidence is low, and the findings are limited by substantial heterogeneity. No consistent benefit was observed for aseptic loosening, periprosthetic fracture, or long-term BMD preservation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.